January 1, 2002The Canadian Journal of Hospital Pharmacy
Arguments against Monitoring Levels of Anti-Factor Xa in Conjunction with Low-Molecular-Weight Heparin Therapy
Key result
Routine monitoring of anti-factor Xa levels during low-molecular-weight heparin therapy is not recommended, as evidence does not support a link between activity, bleeding, and drug efficacy.
Why the study?
Does routine monitoring of anti-factor Xa levels predict bleeding or drug efficacy in patients receiving LMWH therapy for deep vein thrombosis?
Structured PICO
Does routine monitoring of anti-factor Xa levels predict bleeding or drug efficacy in patients receiving LMWH therapy for deep vein thrombosis?
P
Population
Patients receiving low-molecular-weight heparin (LMWH) therapy for deep vein thrombosis
I
Intervention
Routine monitoring of anti-factor Xa concentrations
O
Outcome
Link between anti-factor Xa activity, bleeding, and effect of the drug
Routine monitoring of anti-factor Xa levels during LMWH therapy for DVT is not recommended due to a lack of evidence linking these levels to clinical efficacy or bleeding risk.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Does not support routine anti-Xa monitoring for LMWH in DVT; leaves open targeted use in high-risk subgroups.
Cite This Study
Rosenbloom et al. (2002) conducted a review in Deep vein thrombosis. Monitoring levels of anti-factor Xa was evaluated. Routine monitoring of anti-factor Xa levels during low-molecular-weight heparin therapy is not recommended, as evidence does not support a link between activity, bleeding, and drug efficacy.